血液学の世界市場：洞察、競合情勢、市場予測：2030年

世界の血液学の市場規模は、2023年に21億3,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に7.98%のCAGRで拡大し、2030年には33億8,000万米ドルに達すると予測されています。血液学市場は、血液およびそれに関連する疾患の有病率の上昇、製品開発における研究開発活動の急増、これらの疾患に罹患しやすい高齢化人口の増加により、プラスの成長が促進されています。さらに、低侵襲的介入に対する人気の高まりと認知度の拡大が、これらの機器の需要をさらに押し上げ、2024～2030年の予測期間中の血液学市場の成長に寄与しています。

血液学市場は、さまざまな要因によって製品需要が伸びています。主な要因は、貧血、血液がん、出血性疾患、サラセミア、血液感染症などの血液および関連疾患の有病率の上昇です。

慢性血液疾患は、患者とその家族の健康と生活の質に大きな影響を与えます。疼痛、正常な機能の喪失、抑うつ、不安、経済的負担、長期入院、さらには死亡の原因となることもあります。そのため、慢性血液疾患を適切に治療・管理するためには、血液検査装置が必要となります。これらの機器は、凝固不全の検出、凝固経路の速度、トロンビン濃度の測定に役立ち、また全血に対する薬剤の効果をモニターするためにも使用されます。その用途は極めて広範囲に及び、血液疾患における応用範囲も広いため、これらの機器に対する需要は拡大し、世界血液学市場の牽引役となることが期待されます。

当レポートでは、世界の血液学市場について調査し、市場の概要とともに、タイプ別、用途別、モダリティ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 血液学市場レポートのイントロダクション

第2章 血液学市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 血液学市場の主な要因分析

• 血液学市場の促進要因
• 血液学市場の抑制要因と課題
• 血液学市場の機会

第5章 血液学市場におけるポーターのファイブフォース分析

第6章 血液学市場に対するCOVID-19の影響分析

第7章 血液学市場の概要

• タイプ別
• 用途別
• モダリティ別
• エンドユーザー別
• 地域別

第8章 血液学市場の世界企業シェア分析-主要3～5社

第9章 血液学市場の企業と製品プロファイル

• Sysmex Corporation
• Danaher
• Nihon Kohden Corporation
• Siemens Healthcare GmbH
• Abbott
• Boule Diagnostics
• Bio-Rad Laboratories, Inc.
• Biosystems S.A.
• Diatron
• EKF Diagnostics
• Shenzhen Mindray Bio-Medical Electronics Co.
• Erba Mannheim
• Ortho Clinical Diagnostics
• Abaxis
• Heska Corporation
• F. Hoffmann-La Roche Ltd
• Horiba Ltd.
• Neomedica
• Thermo Fisher Scientific
• Agilent

第10章 KOL の見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Hematology Market in Global (2021-2030)
• Table 4: Hematology Market in Global by Type (2021-2030)
• Table 5: Hematology Market in Global by Application (2021-2030)
• Table 6: Hematology Market in Global by Modality (2021-2030)
• Table 7: Hematology Market in Global by End User (2021-2030)
• Table 8: Hematology Market in Global by Geography (2021-2030)
• Table 9: Hematology Market in North America (2021-2030)
• Table 10: Hematology Market in North America by Country (2021-2030)
• Table 11: Hematology Market in the US (2021-2030)
• Table 12: Hematology Market in Canada (2021-2030)
• Table 13: Hematology Market in Mexico (2021-2030)
• Table 14: Hematology Market in Europe (2021-2030)
• Table 15: Hematology Market in Europe by Country (2021-2030)
• Table 16: Hematology Market in France (2021-2030)
• Table 17: Hematology Market in Germany (2021-2030)
• Table 18: Hematology Market in the United Kingdom (2021-2030)
• Table 19: Hematology Market in Italy (2021-2030)
• Table 20: Hematology Market in Spain (2021-2030)
• Table 21: Hematology Market in Russia (2021-2030)
• Table 22: Hematology Market in Rest of Europe (2021-2030)
• Table 23: Hematology Market in APAC (2021-2030)
• Table 24: Hematology Market in APAC by Country (2021-2030)
• Table 25: Hematology Market in China (2021-2030)
• Table 26: Hematology Market in Japan (2021-2030)
• Table 27: Hematology Market in India (2021-2030)
• Table 28: Hematology Market in Australia (2021-2030)
• Table 29: Hematology Market in South Korea (2021-2030)
• Table 30: Hematology Market in Rest of APAC (2021-2030)
• Table 31: Hematology Market in Rest of World (2021-2030)
• Table 32: Hematology Market in RoW by Region (2021-2030)
• Table 33: Hematology Market in Middle East (2021-2030)
• Table 34: Hematology Market in Africa (2021-2030)
• Table 35: Hematology Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Hematology Market in Global (2021-2030)
• Figure 4: Hematology Market in Global by Type (2021-2030)
• Figure 5: Hematology Market in Global by Application (2021-2030)
• Figure 6: Hematology Market in Global by Modality (2021-2030)
• Figure 7: Hematology Market in Global by End User (2021-2030)
• Figure 8: Hematology Market in Global by Geography (2021-2030)
• Figure 9: Hematology Market in North America (2021-2030)
• Figure 10: Hematology Market in North America by Country (2021-2030)
• Figure 11: Hematology Market in the US (2021-2030)
• Figure 12: Hematology Market in Canada (2021-2030)
• Figure 13: Hematology Market in Mexico (2021-2030)
• Figure 14: Hematology Market in Europe (2021-2030)
• Figure 15: Hematology Market in Europe by Country (2021-2030)
• Figure 16: Hematology Market in France (2021-2030)
• Figure 17: Hematology Market in Germany (2021-2030)
• Figure 18: Hematology Market in the United Kingdom (2021-2030)
• Figure 19: Hematology Market in Italy (2021-2030)
• Figure 20: Hematology Market in Spain (2021-2030)
• Figure 21: Hematology Market in Russia (2021-2030)
• Figure 22: Hematology Market in Rest of Europe (2021-2030)
• Figure 23: Hematology Market in APAC (2021-2030)
• Figure 24: Hematology Market in APAC by Country (2021-2030)
• Figure 25: Hematology Market in China (2021-2030)
• Figure 26: Hematology Market in Japan (2021-2030)
• Figure 27: Hematology Market in India (2021-2030)
• Figure 28: Hematology Market in Australia (2021-2030)
• Figure 29: Hematology Market in South Korea (2021-2030)
• Figure 30: Hematology Market in Rest of APAC (2021-2030)
• Figure 31: Hematology Market in Rest of World (2021-2030)
• Figure 32: Hematology Market in RoW by Region (2021-2030)
• Figure 33: Hematology Market in Middle East (2021-2030)
• Figure 34: Hematology Market in Africa (2021-2030)
• Figure 35: Hematology Market in South America (2021-2030)
• Figure 36: Market Drivers
• Figure 37: Market Barriers
• Figure 38: Marker Opportunities
• Figure 39: PORTER'S Five Force Analysis

Hematology Market By Type (Instruments [Hematology Analyzers, Hematology Cell Counters, Flow Cytometers, Coagulation Analyzers, Others], Kits And Reagents), By Application (Cardiovascular Diseases, Auto-Immune Diseases, Cancer, Diabetes Mellitus, Infectious Diseases, Others), By Modality (Clinical Laboratory Devices, Point Of Care Devices), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising incidence of blood-related disorders and rapid technological developmental activities

Global Hematology Market was valued at USD 2.13 Billion in 2023, growing at a CAGR of 7.98% during the forecast period from 2024 to 2030 to reach USD 3.38 Billion by 2030. The Hematology market is witnessing positive growth owing to the rising prevalence of blood and its related disorders, a surge in the research and development activities in product development, increasing incidences of the aging population who are susceptible to these diseases. Moreover, the growing popularity and expanding awareness of minimally invasive interventions, further pushed for the demand of these devices, thereby contributing to the growth of the Hematology market during the forecast period from 2024-2030.

Hematology Market Dynamics:

The Hematology market is witnessing a growth in product demand owing to various reasons. The major factor responsible is the rising prevalence of blood and related disorders such as anemia, blood cancers, hemorrhagic conditions, thalassemia, and blood infections.

Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, and anxiety, financial burden, long-term hospitalization, and even death. Therefore, to properly treat and manage chronic blood disorders, Hematology devices are required. These devices help to detect clotting deficiencies, measure coagulation pathways speed, thrombin levels, and are also used to monitor the effects of drugs on whole blood. Since their use is quite extensive and offers wide applications in blood disorders, thus the demand for these devices will grow, which in turn is expected to drive the Global Hematology market.

According to the Centers for Disease Control and Prevention 2020, people with hemophilia have unique risk factors that may lead them to heart disease as their life expectancy increases, such as infusion of factor concentrates and infection with HIV. Owing to the growing burden of lifestyle-associated and chronic blood disorders across the globe, the Hematology market has been rising significantly. Similarly, as per Haemophilia Foundation Australia 2022, Haemophilia occurs in 1 in 6,000-10,000 males internationally. According to the same statistics, in Australia, there are more than 3,000 people diagnosed with varying degrees of severity of Haemophilia.

In addition, key players operating in the market are focusing on developing advanced technologically based Hematology devices and reagents. For instance, in March 2019, HORIBA Medical launched a new Yumizen GDDi 2 (D-Dimer) reagent kit in its hemostasis instrument range, which includes the compact Yumizen G200 coagulation analyzer. The kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). Thus, such development by players may help in contributing to patient management that will augment the demand for Global Hematology and will drive the market growth during the forecasted period from 2024-2030.

Moreover, it is predicted that the rising number of elderly patients would transform healthcare delivery and create a larger demand for Hematology. As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure for such patients is expected to double and reach 1.5 billion by 2050. Since the aging population is more prone to blood disorders, therefore it will give rise to more demand for Hematology devices, which will boost the Hematology market. Thus, all these factors are projected to drive the growth of the market for Hematology.

However, the high cost and unavailability of skilled professionals may be certain limiting factors of the Hematology market growth.

The ongoing Coronavirus disease 2019 (COVID-19) pandemic has slightly positively impacted the market for Hematology as hospital admissions for COVID -19 patients were at maximum priority and Hematology was used for corona-infected patients in order to provide supportive treatments. This resulted in the increased demand for Hematology during the pandemic. Moreover, the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape post pandemically made the resumption of regular healthcare services, which kept the demand for these products on course in the Hematology market.

Hematology Market Segment Analysis:

Hematology Market By Type (Instruments [Hematology Analyzers, Hematology Cell Counters, Flow Cytometers, Coagulation Analyzers, Others], Kits and Reagents), By Application (Cardiovascular Diseases, Auto-immune Diseases, Cancer, Diabetes Mellitus, Infectious Diseases, Others), By Modality (Clinical Laboratory Devices, Point of Care Devices), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Type segment of the Hematology market, Coagulation Analyzers are estimated to hold a higher share in the Hematology market during the forecast period (2024-2030). This can be attributed to the specific features associated with these devices.

The rapid growth of this segment can be attributed to the minimal interaction which drastically reduces the chances of infections, errors, rapid precision which ensures reproducibility, reduced personnel to do the task, and most importantly, a large number of samples that can be processed at the same time.

The advantage associated with Coagulation Analyzers is that they can be used to measure a coagulation pathway speed, as well as thrombolin and thromboplastin levels in as low as a few minutes. A coagulation analyzer is specifically designed to handle a large number of patients, permitting the storage of up to 600 patient tests per well, which further increases their demand, thereby driving the growth of the overall Hematology market.

Additionally, a new development in the product lines and new product launches are bolstering the segment growth of the Hematology market during the forecasted period.

North America is expected to dominate the overall Hematology Market:

Among all the regions, North America is expected to account for the largest share in the Global Hematology market. This domination is owing to the rising prevalence of chronic blood diseases, increased incidence of these disorders in the aging population, and improved product launches are expected to aid in the growth of the North America Hematology Market.

The cases of blood disease are rising constantly and these cases promote the need for use of Hematology in disease treatment in North America. For instance, as per the National Hemophilia Foundation 2022, between 30,000- 33,000 people are living with hemophilia in the US.

Additionally, according to CDC 2020, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year in the United States.

Moreover, according to the Canadian Chronic Disease Surveillance System, heart disease is the leading cause of disability-adjusted life years (DALYs) lost due to ill-health, disability, or early death worldwide.

Furthermore, the increased emphasis on product development activities and the high interest of device manufacturers in accessing local markets through collaborative agreements further aid in the growth of the regional markets for Hematology. For instance, in March 2022, PixCell Medical, innovator of rapid hematology testing solutions at the point of care, announced its exclusive distribution agreement with Katalyst Diagnostics, a new division of Katalyst Laboratories, to distribute HemoScreen. HemoScreen is the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care (POC) use.

These kinds of partnerships in the local markets may drive the product demand in the market. Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Hematology market during the forecast period.

Hematology Market Key Players:

Some of the key market players operating in the Hematology market include Sysmex Corporation, Danaher, Nihon Kohden Corporation, Siemens Healthcare GmbH, Abbott, Boule Diagnostics, Bio-Rad Laboratories, Inc., Biosystems S.A., Diatron, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Erba Mannheim, Ortho Clinical Diagnostics, Abaxis, Heska Corporation, F. Hoffmann-La Roche Ltd, Horiba Ltd., Neomedica, Thermo Fisher Scientific, Agilent, and others.

Recent Developmental Activities in the Hematology Market:

In February 2022, Horiba Medical announced that its new generation of the Microsemi CRP hematology analyzer, the Microsemi CRP LC-767G, has received CE marking. The new analyzer is more compact and has enhanced software and network connectivity with higher memory. It also includes a new parameter, the Granulocytes-to-Lymphocytes Ratio.

In January 2022, PixCell Medical announced that it has signed a distribution agreement for its HemoScreen Hematology Analyzer in Sweden with Triolab. HemoScreen is a portable, point-of-care complete blood count analyzer that uses disposable cartridges that include all necessary reagents and provides results from a single drop of blood from a fingerstick.

In July 2020, Sysmex launched next-generation fully automated blood coagulation analyzers CN-6000 and CN-3000 in the EMEA region.

Key Takeaways from the Hematology Market Report Study

• Market size analysis for current Hematology market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Hematology market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global Hematology market.
• Various opportunities available for the other competitor in the Hematology market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current Hematology market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Hematology market growth in the coming future?

Target Audience who can be benefited from this Hematology Market Report Study

• Hematology products providers
• Research organizations and consulting companies
• Hematology-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Hematology
• Various End-users who want to know more about the Hematology market and latest technological developments in the Hematology market.

Frequently Asked Questions for the Hematology Market:

1. What is Hematology?

Hematology is the branch of medicine related to the study of the cause, prognosis, treatment, and prevention of diseases related to blood.

2. What is the market for Global Hematology?

Global Hematology Market was valued at USD 2.13 Billion in 2023, growing at a CAGR of 7.98% during the forecast period from 2024 to 2030 to reach USD 3.38 Billion by 2030.

3. What are the drivers for the Global Hematology Market?

The Hematology market is witnessing a positive market growth owing to the rising prevalence of blood and its related disorders, a surge in the research and development activities in product development, increasing incidences of the aging population who are susceptible to these diseases. Moreover, the growing popularity and expanding awareness of minimally invasive interventions, further pushed for the demand of these devices, thereby contributing to the growth of the Hematology market during the forecast period from 2024-2030.

4. Who are the key players operating in the Global Hematology Market?

Some of the key market players operating in the Hematology market include Sysmex Corporation, Danaher, Nihon Kohden Corporation, Siemens Healthcare GmbH, Abbott, Boule Diagnostics, Bio-Rad Laboratories, Inc., Biosystems S.A., Diatron, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Erba Mannheim, Ortho Clinical Diagnostics, Abaxis, Heska Corporation, F. Hoffmann-La Roche Ltd, Horiba Ltd., Neomedica, Thermo Fisher Scientific, Agilent, and others.

5. Which region has the highest share in Hematology Market?

North America is expected to hold the highest share in the revenue in the Hematology market during the forecast period. This domination is owing to the rising prevalence of chronic blood diseases, increased incidence of these disorders in the aging population, and improved product launches are expected to aid in the growth of the North America Hematology Market.

Table of Contents

1.Hematology Market Report Introduction

2.Hematology Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Hematology Market Key Factors Analysis

• 4.1. Hematology Market Drivers
  • 4.1.1. The Rising Prevalence of Blood and its Related Disorders
  • 4.1.2. A Surge in the Research and Development Activities in Product Development
  • 4.1.3. Increasing Incidences of the Aging Population who are Susceptible to these Diseases
  • 4.1.4. The Growing Popularity and Expanding Awareness of Minimally Invasive Interventions
• 4.2. Hematology Market Restraints and Challenges
  • 4.2.1. High Cost
  • 4.2.2. Unavailability of Skilled Professionals
• 4.3. Hematology Market Opportunities
  • 4.3.1. The Rise in Investment By Market Players For Technological Development
  • 4.3.2. Targeting Emerging Markets for Product Launches

5. Hematology Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Hematology Market

7. Hematology Market Layout

• 7.1. By Type
  • 7.1.1. Instruments
    • 7.1.1.1. Hematology Analyzers
    • 7.1.1.2. Hematology Cell Counters
    • 7.1.1.3. Flow Cytometers
    • 7.1.1.4. Coagulation Analyzers
    • 7.1.1.5. Others
  • 7.1.2. Kits and Reagents
• 7.2. By Application
  • 7.2.1. Cardiovascular Diseases
  • 7.2.2. Auto-immune Diseases
  • 7.2.3. Cancer
  • 7.2.4. Diabetes Mellitus
  • 7.2.5. Infectious Diseases
  • 7.2.6. Others
• 7.3. By Modality
  • 7.3.1. Clinical Laboratory Devices
  • 7.3.2. Point of Care Devices
• 7.4. By End User
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Diagnostic Laboratories
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. North America Hematology Market, by Country
    • 7.5.1.1.1. United States
    • 7.5.1.1.2. Canada
    • 7.5.1.1.3. Mexico
  • 7.5.2. Europe
    • 7.5.2.1. Europe Hematology Market, by Country
    • 7.5.2.1.1. France
    • 7.5.2.1.2. Germany
    • 7.5.2.1.3. United Kingdom
    • 7.5.2.1.4. Italy
    • 7.5.2.1.5. Spain
    • 7.5.2.1.6. Russia
    • 7.5.2.1.7. Rest of Europe
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. Asia-Pacific Hematology Market, by Country
    • 7.5.3.1.1. China
    • 7.5.3.1.2. Japan
    • 7.5.3.1.3. India
    • 7.5.3.1.4. Australia
    • 7.5.3.1.5. South Korea
    • 7.5.3.1.6. Rest of Asia Pacific
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. RoW Hematology Market, by Region
    • 7.5.4.1.1. Middle East
    • 7.5.4.1.2. Africa
    • 7.5.4.1.3. South America

8. Hematology Market Global Company Share Analysis - Key 3-5 Companies

9. Hematology Market Company and Product Profiles

• 9.1 Sysmex Corporation
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Danaher
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Nihon Kohden Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Siemens Healthcare GmbH
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Abbott
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Boule Diagnostics
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Bio-Rad Laboratories, Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Biosystems S.A.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Diatron
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. EKF Diagnostics
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Shenzhen Mindray Bio-Medical Electronics Co.
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Erba Mannheim
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Ortho Clinical Diagnostics
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Abaxis
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Heska Corporation
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. F. Hoffmann-La Roche Ltd
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Horiba Ltd.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Neomedica
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Thermo Fisher Scientific
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Agilent
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us